Top

Published in:

01-01-2010 | Disease Management

Aggressive treatment is essential to reduce cardiovascular risk in diabetic hypertensive patients

Published in: Drugs & Therapy Perspectives | Issue 1/2010

Excerpt

Patients with type 2 diabetes mellitus and hypertension are at increased risk of vascular complications, and attainment of blood pressure goals (<130/80 mmHg) is crucial to reduce this risk. All major antihypertensive drug classes are effective, although ACE inhibitors or angiotensin receptor blockers in combination with thiazide diuretics are usually preferred. …

Shammas NW, Sica DA, Toth PP. A guide to the management of blood pressure in the diabetic hypertensive patient. Am J Cardiovasc Drugs 2009; 9(3): 149–62PubMed

Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. JAMA 2003; 289(19): 2560–72PubMedCrossRef

Hypertension in Diabetes Study Investigators. Hypertension in Diabetes Study (HDS): II, increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11(3): 319–25CrossRef

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12; 317 (7160): 703–13

Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321(7258): 405–12PubMedCrossRef

Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321(7258): 412–9PubMedCrossRef

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351(9118): 1755–62PubMedCrossRef

Kaplan N, Mendis S, Poulter N, et al. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 2003 Nov; 21(11): 1983–92CrossRef

Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87PubMedCrossRef

10.

Palmer BF. Improving BP control with combined renin-angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. Am J Cardiovasc Drugs 2008; 8(1): 9–14PubMedCrossRef

11.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–97CrossRef

12.

American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008; 31Suppl. 1: S12–54CrossRef

13.

Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. ONTARGET investigators. Lancet 2008 Aug 16; 372(9638): 547–53PubMedCrossRef

14.

Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 2008; 358(15): 1547–59PubMedCrossRef

15.

Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26(7): 1282–9PubMedCrossRef

16.

Verberk WJ, Kroon AA, Kessels AG, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Home versus office measurement, reduction of unnecessary treatment study investigators. Hypertension 2007; 50(6): 1019–25PubMedCrossRef

17.

Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366(9502): 2026–33PubMedCrossRef

18.

Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med 2008; 358(24): 2560–72PubMedCrossRef

19.

Palmer BF. Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system. N Engl J Med 2004; 351(6): 585–92PubMedCrossRef

Title: Aggressive treatment is essential to reduce cardiovascular risk in diabetic hypertensive patients
Publication date: 01-01-2010
Publisher: Springer International Publishing
Published in: Drugs & Therapy Perspectives / Issue 1/2010
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.2165/11204030-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Aggressive treatment is essential to reduce cardiovascular risk in diabetic hypertensive patients

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus

Ferric carboxymaltose: a guide to its use in iron-deficiency anaemia

Fesoterodine: a guide to its use in overactive bladder syndrome

Worldwide control of trachoma involves a strategy combining surgery, antibacterials, facial cleanliness and environmental improvements

News from the 38th European Symposium on Clinical Pharmacy; 3–6 November 2009; Geneva

First reports of serious adverse drug reactions in recent weeks